Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Samsung Bioepis Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

15 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Biotecnologia
Salute
Farmaceutica
Ottica
Industria
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
01/12/2025
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Farmaceutica
Salute
Sanità
Mercato del lavoro
Industria
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
29/10/2025
Mercato del lavoro
Industria
Salute
Scienza
Farmaceutica
Ottica
Biotecnologia
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
23/10/2025
Biotecnologia
Farmaceutica
Salute
Sanità
Analisi di mercato
Industria
Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
20/10/2025
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
21/07/2025
Biotecnologia
Sanità
Igiene alimentare
Salute
Farmaceutica
Analisi di mercato
Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
17/07/2025
Salute
Sanità
Farmaceutica
Ottica
Biotecnologia
Mercato del lavoro
Industria
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
14/07/2025
Industria
Salute
Sanità
Farmaceutica
Biotecnologia
Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0
12/06/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Eventi
Industria
Analisi di mercato
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
Fonte
Samsung Bioepis Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0